-
FTO-mediated DSP m6A demethylation promotes an aggressive subtype of growth hormone-secreting pituitary neuroendocrine tumors Mol. Cancer (IF 27.7) Pub Date : 2024-09-20 Yunzhi Zou, Xiaoqiong Bao, Depei Li, Zhen Ye, Rong Xiang, Yuanzhong Yang, Zhe Zhu, Ziming Chen, Lingxing Zeng, Chunling Xue, Hongzhe Zhao, Boyuan Yao, Qilin Zhang, Zeming Yan, Zekun Deng, Jintong Cheng, Guanghao Yue, Wanming Hu, Jixiang Zhao, Ruihong Bai, Zhenhua Zhang, Aiqun Liu, Jialiang Zhang, Zhixiang Zuo, Xiaobing Jiang
Growth hormone-secreting pituitary neuroendocrine tumors can be pathologically classified into densely granulated (DGGH) and sparsely granulated types (SGGH). SGGH is more aggressive and associated with a poorer prognosis. While epigenetic regulation is vital in tumorigenesis and progression, the role of N6-methyladenosine (m6A) in aggressive behavior has yet to be elucidated. We performed m6A-sequencing
-
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia Mol. Cancer (IF 27.7) Pub Date : 2024-09-20 Verónica Alonso-Pérez, Klaudia Galant, Fabien Boudia, Elie Robert, Zakia Aid, Laurent Renou, Vilma Barroca, Saryiami Devanand, Loélia Babin, Virginie Rouiller-Fabre, Delphine Moison, Didier Busso, Guillaume Piton, Christophe Metereau, Nassera Abermil, Paola Ballerini, Pierre Hirsch, Rima Haddad, Jelena Martinovic, Arnaud Petit, Hélène Lapillonne, Erika Brunet, Thomas Mercher, Françoise Pflumio
Several fusion oncogenes showing a higher incidence in pediatric acute myeloid leukemia (AML) are associated with heterogeneous megakaryoblastic and other myeloid features. Here we addressed how developmental mechanisms influence human leukemogenesis by ETO2::GLIS2, associated with dismal prognosis. We created novel ETO2::GLIS2 models of leukemogenesis through lentiviral transduction and CRISPR-Cas9
-
Altered metabolism in cancer: insights into energy pathways and therapeutic targets Mol. Cancer (IF 27.7) Pub Date : 2024-09-18 Muhammad Tufail, Can-Hua Jiang, Ning Li
Cancer cells undergo significant metabolic reprogramming to support their rapid growth and survival. This study examines important metabolic pathways like glycolysis, oxidative phosphorylation, glutaminolysis, and lipid metabolism, focusing on how they are regulated and their contributions to the development of tumors. The interplay between oncogenes, tumor suppressors, epigenetic modifications, and
-
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective Mol. Cancer (IF 27.7) Pub Date : 2024-09-18 Yang Xiao, Yongsheng Li, Huakan Zhao
Metabolic reprogramming drives the development of an immunosuppressive tumor microenvironment (TME) through various pathways, contributing to cancer progression and reducing the effectiveness of anticancer immunotherapy. However, our understanding of the metabolic landscape within the tumor-immune context has been limited by conventional metabolic measurements, which have not provided comprehensive
-
Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance Mol. Cancer (IF 27.7) Pub Date : 2024-09-16 Wei Dai, Jianwei Zhou, Ting Chen
Ovarian cancer (OC) is one of the most prevalent and lethal gynecological malignancies, with high mortality primarily due to its aggressive nature, frequent metastasis, and resistance to standard therapies. Recent research has highlighted the critical role of extracellular vesicles (EVs) in these processes. EVs, secreted by living organisms and carrying versatile and bioactive cargoes, play a vital
-
Neutrophils in the premetastatic niche: key functions and therapeutic directions Mol. Cancer (IF 27.7) Pub Date : 2024-09-14 Jiachi Jia, Yuhang Wang, Mengjia Li, Fuqi Wang, Yingnan Peng, Junhong Hu, Zhen Li, Zhilei Bian, Shuaixi Yang
Metastasis has been one of the primary reasons for the high mortality rates associated with tumours in recent years, rendering the treatment of current malignancies challenging and representing a significant cause of recurrence in patients who have undergone surgical tumour resection. Halting tumour metastasis has become an essential goal for achieving favourable prognoses following cancer treatment
-
Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-09-14 Qiang Liu, Yujing Guan, Shenglong Li
Correction: Mol Cancer 23, 183 (2024) https://doi.org/10.1186/s12943-024-02095-8 Following publication of the original article [1], the author reported that the published PDF version is incorrect as the information such as “(See Fig. 5)”, “(Fig. 4; Table 3)”, and “[170]” need to be removed and updated accordingly as shown below. The original article has been corrected. The sentences currently read:
-
Exosomal miR-4745-5p/3911 from N2-polarized tumor-associated neutrophils promotes gastric cancer metastasis by regulating SLIT2 Mol. Cancer (IF 27.7) Pub Date : 2024-09-13 Jiahui Zhang, Dan Yu, Cheng Ji, Maoye Wang, Min Fu, Yu Qian, Xiaoxin Zhang, Runbi Ji, Chong Li, Jianmei Gu, Xu Zhang
Tumor cells remodel the phenotype and function of tumor microenvironment (TME) cells to favor tumor progression. Previous studies have shown that neutrophils in TME are polarized to N2 tumor-associated neutrophils (TANs) by tumor derived factors, thus promoting tumor growth and metastasis, angiogenesis, therapy resistance, and immunosuppression. Exosomes act as critical intercellular messengers in
-
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics Mol. Cancer (IF 27.7) Pub Date : 2024-09-13 Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine A. Bellera, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, Antoine Italiano
Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors in advanced gastric cancer (AGC). Early phase studies involving Asian patients demonstrated encouraging anti-tumor efficacies. We report the results of the REGOMUNE phase II study, in which Caucasian
-
Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2024-09-13 Yonger Chen, Jian Liang, Shuxian Chen, Nan Lin, Shuoxi Xu, Jindian Miao, Jing Zhang, Chen Chen, Xin Yuan, Zhuoya Xie, Enlin Zhu, Mingsheng Cai, Xiaoli Wei, Shaozhen Hou, Hailin Tang
Colitis-associated colorectal cancer (CAC) frequently develops in patients with inflammatory bowel disease (IBD) who have been exposed to a prolonged state of chronic inflammation. The investigation of pharmacological agents and their mechanisms to prevent precancerous lesions and inhibit their progression remains a significant focus and challenge in CAC research. Previous studies have demonstrated
-
Correction: Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA Mol. Cancer (IF 27.7) Pub Date : 2024-09-12 Min Kang, Bo Tang, Jixi Li, Ziyan Zhou, Kang Liu, Rensheng Wang, Ziyan Jiang, Fangfang Bi, David Patrick, Dongin Kim, Anirban K. Mitra, Yang Yang-Hartwich
Correction: Mol Cancer 19, 143 (2020) https://doi.org/10.1186/s12943-020-01248-9 Recently in a re-examination of our previously published paper [1], “Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA” [Molecular Cancer 19, article number 143 (2020)], we found two errors. The first error is that we presented the wrong primer sequences for GAPDH in the Supplemental
-
Correction: Prostate cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly Mol. Cancer (IF 27.7) Pub Date : 2024-09-11 Qing Shi, Yasheng Zhu, Jian Ma, Kun Chang, Dongling Ding, Yang Bai, Kun Gao, Pingzhao Zhang, Ren Mo, Kai Feng, Xiaying Zhao, Liang Zhang, Huiru Sun, Dongyue Jiao, Yingji Chen, Yinghao Sun, Shi-min Zhao, Haojie Huang, Yao Li, Shancheng Ren, Chenji Wang
Correction: Mol Cancer 18, 170 (2019) https://doi.org/10.1186/s12943-019-1096-x The authors apologize for the errors in Fig. 2. In the original published version [1], the western blot image of Actin in Fig. 2D was mistakenly uploaded. The Western blot image of BRD4 in Fig. 2G was mistakenly uploaded. The Western blot one lane of FLAG (Input) in Fig. 2K was inadvertently omitted due to a careless mistake
-
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes Mol. Cancer (IF 27.7) Pub Date : 2024-09-09 Yikan Sun, Eloy Yinwang, Shengdong Wang, Zenan Wang, Fangqian Wang, Yucheng Xue, Wenkan Zhang, Shenzhi Zhao, Haochen Mou, Shixin Chen, Lingxiao Jin, Binghao Li, Zhaoming Ye
CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity of CD8+ tumour infiltrating lymphocytes, and made it increasingly clear that the bulk of the endogenous and therapeutically induced tumour-suppressive momentum hinges on a particular selection of CD8+ T cells with advantageous
-
Advances on immunotherapy for osteosarcoma Mol. Cancer (IF 27.7) Pub Date : 2024-09-09 Shengnan Yu, Xudong Yao
Osteosarcoma is the most common primary bone cancer in children and young adults. Limited progress has been made in improving the survival outcomes in patients with osteosarcoma over the past four decades. Especially in metastatic or recurrent osteosarcoma, the survival rate is extremely unsatisfactory. The treatment of osteosarcoma urgently needs breakthroughs. In recent years, immunotherapy has achieved
-
Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications Mol. Cancer (IF 27.7) Pub Date : 2024-09-07 Zhengjun Lin, Guoqing Li, Ke Jiang, Zhihong Li, Tang Liu
Cancer-associated fibroblasts (CAFs) are a diverse stromal cell population within the tumour microenvironment, where they play fundamental roles in cancer progression and patient prognosis. Multiple lines of evidence have identified that CAFs are critically involved in shaping the structure and function of the tumour microenvironment with numerous functions in regulating tumour behaviours, such as
-
Unraveling the key role of chromatin structure in cancer development through epigenetic landscape characterization of oral cancer Mol. Cancer (IF 27.7) Pub Date : 2024-09-06 Yue Xue, Lu Liu, Ye Zhang, Yueying He, Jingyao Wang, Zicheng Ma, Tie-jun Li, Jianyun Zhang, Yanyi Huang, Yi Qin Gao
Epigenetic alterations, such as those in chromatin structure and DNA methylation, have been extensively studied in a number of tumor types. But oral cancer, particularly oral adenocarcinoma, has received far less attention. Here, we combined laser-capture microdissection and muti-omics mini-bulk sequencing to systematically characterize the epigenetic landscape of oral cancer, including chromatin architecture
-
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma Mol. Cancer (IF 27.7) Pub Date : 2024-09-06 Yau-Tuen Chan, Cheng Zhang, Junyu Wu, Pengde Lu, Lin Xu, Hongchao Yuan, Yibin Feng, Zhe-Sheng Chen, Ning Wang
Liver cancer is a global health challenge, causing a significant social-economic burden. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is highly heterogeneous in terms of molecular and cellular signatures. Early-stage or small tumors are typically treated with surgery or ablation. Currently, chemotherapies and immunotherapies are the best treatments for unresectable
-
NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer Mol. Cancer (IF 27.7) Pub Date : 2024-09-06 Chrispus Ngule, Ruyi Shi, Xingcong Ren, Hongyan Jia, Felix Oyelami, Dong Li, Younhee Park, Jinhwan Kim, Hami Hemati, Yi Zhang, Xiaofang Xiong, Andrew Shinkle, Nathan L. Vanderford, Sara Bachert, Binhua P. Zhou, Jianlong Wang, Jianxun Song, Xia Liu, Jin-Ming Yang
Triple negative breast cancer (TNBC) is a particularly lethal breast cancer (BC) subtype driven by cancer stem cells (CSCs) and an immunosuppressive microenvironment. Our study reveals that nucleus accumbens associated protein 1 (NAC1), a member of the BTB/POZ gene family, plays a crucial role in TNBC by maintaining tumor stemness and influencing myeloid-derived suppressor cells (MDSCs). High NAC1
-
Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance Mol. Cancer (IF 27.7) Pub Date : 2024-09-06 Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, Misha Mao, Shuai Zhang, Lisa Derosa, Julie Le Naour, Flavia Lambertucci, Silvia Mingoia, Uxía Nogueira-Recalde, Rafael Mena-Osuna, Irene Herranz-Montoya, Nabil Djouder, Sylvain Baulande, Hui Pan, Adrien Joseph, Meriem Messaoudene, Bertrand Routy, Marine Fidelle, Tarek Ben Ahmed, Olivier Caron, Pierre Busson, David Boulate, Mélanie Deschasaux-Tanguy
The plasma concentrations of acyl coenzyme A binding protein (ACBP, also known as diazepam-binding inhibitor, DBI, or ‘endozepine’) increase with age and obesity, two parameters that are also amongst the most important risk factors for cancer. We measured ACBP/DBI in the plasma from cancer-free individuals, high-risk patients like the carriers of TP53 or BRCA1/2 mutations, and non-syndromic healthy
-
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment Mol. Cancer (IF 27.7) Pub Date : 2024-09-06 Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen
Peritumoral hepatocytes are critical components of the liver cancer microenvironment, However, the role of peritumoral hepatocytes in the local tumor immune interface and the underlying molecular mechanisms have not been elucidated. YTHDF2, an RNA N6-methyladenosine (m6A) reader, is critical for liver tumor progression. The function and regulatory roles of YTHDF2 in peritumoral hepatocytes are unknown
-
The prognostic effect of infiltrating immune cells is shaped by proximal M2 macrophages in lung adenocarcinoma Mol. Cancer (IF 27.7) Pub Date : 2024-09-04 Jian-Rong Li, Vikram Shaw, Yupei Lin, Xiang Wang, Muhammad Aminu, Yong Li, Jia Wu, Jianjun Zhang, Christopher I. Amos, Chao Cheng
The spatial arrangement of immune cells within the tumor microenvironment (TME) and their interactions play critical roles in the initiation and development of cancer. Several advanced technologies such as imaging mass cytometry (IMC) providing the immunological landscape of the TME with single-cell resolution. In this study, we develop a new method to quantify the spatial proximity between different
-
LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer Mol. Cancer (IF 27.7) Pub Date : 2024-09-02 Bo Wu, Xin Huang, Xiang Shi, Meixi Jiang, Hongxu Liu, Li Zhao
Great progress has been made in utilizing immune checkpoint blockade (ICB) for the treatment of non-small-cell lung cancer (NSCLC). Therapies targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1, expressed on tumor cells, have demonstrated potential in improving patient survival rates. An unresolved issue involves immune suppression induced by exosomal PD-L1 within the tumor microenvironment
-
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-09-02 Qiang Liu, Yujing Guan, Shenglong Li
Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is constitutively expressed on various immune cells, epithelial cells, and cancer cells, where it functions as a co-stimulatory molecule capable of impairing T-cell mediated immune responses. Upon binding to PD-1 on activated T-cells, the PD-1/PD-L1
-
Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets Mol. Cancer (IF 27.7) Pub Date : 2024-09-02 Ken Asada, Syuzo Kaneko, Ken Takasawa, Kouya Shiraishi, Norio Shinkai, Yoko Shimada, Satoshi Takahashi, Hidenori Machino, Kazuma Kobayashi, Amina Bolatkan, Masaaki Komatsu, Masayoshi Yamada, Mototaka Miyake, Hirokazu Watanabe, Akiko Tateishi, Takaaki Mizuno, Yu Okubo, Masami Mukai, Tatsuya Yoshida, Yukihiro Yoshida, Hidehito Horinouchi, Shun-Ichi Watanabe, Yuichiro Ohe, Yasushi Yatabe, Takashi Kohno
The cancer genome contains several driver mutations. However, in some cases, no known drivers have been identified; these remaining areas of unmet needs, leading to limited progress in cancer therapy. Whole-genome sequencing (WGS) can identify non-coding alterations associated with the disease. Consequently, exploration of non-coding regions using WGS and other omics data such as ChIP-sequencing (ChIP-seq)
-
Cellular senescence and SASP in tumor progression and therapeutic opportunities Mol. Cancer (IF 27.7) Pub Date : 2024-08-31 Zening Dong, Yahan Luo, Zhangchen Yuan, Yu Tian, Tianqiang Jin, Feng Xu
Cellular senescence (CS), a permanent and irreversible arrest of the cell cycle and proliferation leading to the degeneration of cellular structure and function, has been implicated in various key physiological and pathological processes, particularly in cancer. Initially, CS was recognized as a barrier to tumorigenesis, serving as an intrinsic defense mechanism to protect cells from malignant transformation
-
Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastoma Mol. Cancer (IF 27.7) Pub Date : 2024-08-31 Thale K. Olsen, Jörg Otte, Shenglin Mei, Bethel Tesfai Embaie, Polina Kameneva, Huaitao Cheng, Teng Gao, Vasilios Zachariadis, Ioanna Tsea, Åsa Björklund, Emil Kryukov, Ziyi Hou, Anna Johansson, Erik Sundström, Tommy Martinsson, Susanne Fransson, Jakob Stenman, Shahrzad Shirazi Fard, John Inge Johnsen, Per Kogner, Igor Adameyko, Martin Enge, Peter V. Kharchenko, Ninib Baryawno
Neuroblastoma (NB) is a heterogeneous embryonal malignancy and the deadliest tumor of infancy. It is a complex disease that can result in diverse clinical outcomes. In some children, tumors regress spontaneously. Others respond well to existing treatments. But for the high-risk group, which constitutes approximately 40% of all patients, the prognosis remains dire despite collaborative efforts in basic
-
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression Mol. Cancer (IF 27.7) Pub Date : 2024-08-30 Zhenqiang Sun, Yanxin Xu, Chaohua Si, Xiaoke Wu, Yaxin Guo, Chen Chen, Chengzeng Wang
Plenty of circRNAs have been reported to play an important role in colorectal cancer (CRC), while the reason of abnormal circRNA expression in cancer still keep elusive. Here, we found that m7G RNA modifications were enriched in some circRNAs, these m7G modifications in circRNAs were catalyzed by METTL1, and the GG motif was the main site preference for m7G modifications in circRNAs. We further confirmed
-
Writers, readers, and erasers RNA modifications and drug resistance in cancer Mol. Cancer (IF 27.7) Pub Date : 2024-08-30 Di Chen, Xinyu Gu, Yeltai Nurzat, Lixia Xu, Xueyuan Li, Lixin Wu, Henan Jiao, Peng Gao, Xuqiang Zhu, Dongming Yan, Shaohua Li, Chen Xue
Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing to this resistance is the epigenetic alteration of gene expression via RNA modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), pseudouridine (Ψ), and adenosine-to-inosine (A-to-I) editing
-
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance Mol. Cancer (IF 27.7) Pub Date : 2024-08-27 Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, Weixue Wang, Fan Wu, Yumin Wang, Yu Wang
The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this
-
Assessment of SWI/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer Mol. Cancer (IF 27.7) Pub Date : 2024-08-27 Kai Zhuang, Lishan Wang, Chengyu Lu, Zhiping Liu, Dongli Yang, Hao Zhong, Jiami Zou, Aamir Fahira, Jiaojiao Wang, Zunnan Huang
Recent research has uncovered a surprisingly high occurrence of aberrant expression and mutations in the genes that encode subunits of the SWI/SNF chromatin-remodeling complexes (SCRC). Nevertheless, the carcinogenic effects of aberrant expression and mutations in SWI/SNF genes have only been acknowledged in recent times, resulting in a comparatively limited understanding of these modifications. In
-
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-08-26 Xueting Xia, Zongxin Yang, Qisi Lu, Zhenyun Liu, Lei Wang, Jinwen Du, Yuhua Li, Dong-Hua Yang, Shaojie Wu
In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment efficacy. Current CAR-T therapies are particularly discouraging for solid tumor treatment. The immunosuppressive microenvironment of tumors affects CAR-T cells, limiting the treatment’s effectiveness
-
Induction of circulating ABCB1 transcripts under platinum-based chemotherapy indicates poor prognosis and a bone micrometastatic phenotype in ovarian cancer patients Mol. Cancer (IF 27.7) Pub Date : 2024-08-23 Franziska Maria Schwarz, Jan Dominik Kuhlmann, Jorrin Kämpfer, Anna Klimova, Daniel Martin Klotz, Lisa Freitag, Pia Herrmann, Viktoria Zinnow, Janice Smith, Theresia Scheller, Wolfgang Walther, Pauline Wimberger, Ulrike Stein
The drug efflux transporter P-glycoprotein, encoded by the ABCB1 gene, promotes acquired chemoresistance. We explored the presence and clinical relevance of circulating cell-free ABCB1 transcripts (cfABCB1tx) in ovarian cancer patients (173 longitudinal serum samples from 79 cancer patients) using digital droplet PCR. cfABCB1tx were readily detectable at primary diagnosis (median 354 mRNA copies/20
-
Integration of multiomics features for blood-based early detection of colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2024-08-22 Yibo Gao, Dandan Cao, Mengfan Li, Fuqiang Zhao, Pei Wang, Shiwen Mei, Qianqian Song, Pei Wang, Yanli Nie, Wei Zhao, Sizhen Wang, Hai Yan, Xishan Wang, Yuchen Jiao, Qian Liu
Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness or suboptimal patient adherence. Recently, liquid biopsy employing plasma cell-free DNA (cfDNA) has emerged as a potential noninvasive screening technique for various malignancies. In this research, we
-
The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor’s biology and their translational prospects Mol. Cancer (IF 27.7) Pub Date : 2024-08-22 Margherita Luongo, Pasqualina Laurenziello, Giuseppe Cesta, Anna Maria Bochicchio, Ludmila Carmen Omer, Geppino Falco, Maria Rita Milone, Francesca Cibarelli, Sabino Russi, Simona Laurino
Exosomes mediate cell-to-cell crosstalk involving a variety of biomolecules through an intricate signaling network. In recent years, the pivotal role of exosomes and their non-coding RNAs cargo in the development and progression of several cancer types clearly emerged. In particular, tumor bulk and its microenvironment co-evolve through cellular communications where these nanosized extracellular vesicles
-
Circular RNAs in tumor immunity and immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-08-21 Wenjie Zhang, Chen Xu, Zhipeng Yang, Jingshi Zhou, Wei Peng, Xuan Zhang, Haimin Li, Shibin Qu, Kaishan Tao
Circular RNAs (circRNAs) are unique noncoding RNAs that have a closed and stable loop structure generated through backsplicing. Due to their conservation, stability and tissue specificity, circRNAs can potentially be used as diagnostic indicators and therapeutic targets for certain tumors. Many studies have shown that circRNAs can act as microRNA (miRNA) sponges, and engage in interactions with proteins
-
The role of microRNAs in the gastric cancer tumor microenvironment Mol. Cancer (IF 27.7) Pub Date : 2024-08-20 Xianzhe Yu, Yin Zhang, Fengming Luo, Qinghua Zhou, Lingling Zhu
Gastric cancer (GC) is one of the deadliest malignant tumors with unknown pathogenesis. Due to its treatment resistance, high recurrence rate, and lack of reliable early detection techniques, a majority of patients have a poor prognosis. Therefore, identifying new tumor biomarkers and therapeutic targets is essential. This review aims to provide fresh insights into enhancing the prognosis of patients
-
Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer Mol. Cancer (IF 27.7) Pub Date : 2024-08-20 Yang Chen, Keren Jia, Xiaoyi Chong, Yi Xie, Lei Jiang, Haoxin Peng, Dan Liu, Jiajia Yuan, Yanyan Li, Xujiao Feng, Yu Sun, Jian Li, Xiaotian Zhang, Lin Shen
In the KEYNOTE-811 study, anti-HER2 and immunotherapy treatments resulted in longer survival in HER2-positive gastric cancer patients with CPS ≥ 1, whereas CPS < 1 patients lacked notable benefits. We studied this in a real-world cohort of 106 HER2-positive, CPS < 1 patients and found no survival differences between those treated with anti-HER2 therapy alone or with added immunotherapy. Thus, we investigate
-
Targeting circ-0034880-enriched tumor extracellular vesicles to impede SPP1highCD206+ pro-tumor macrophages mediated pre-metastatic niche formation in colorectal cancer liver metastasis Mol. Cancer (IF 27.7) Pub Date : 2024-08-20 Jing Zhou, Qing Song, Haoze Li, Yicun Han, Yunzhou Pu, Ling Li, Wenqing Rong, Xiaodie Liu, Ziyuan Wang, Jian Sun, Yuqing Song, Xueyan Hu, Guanghao Zhu, Huirong Zhu, Liu Yang, Guangbo Ge, Hongshan Li, Qing Ji
Information transmission between primary tumor cells and immunocytes or stromal cells in distal organs is a critical factor in the formation of pre-metastatic niche (PMN). Understanding this mechanism is essential for developing effective therapeutic strategy against tumor metastasis. Our study aims to prove the hypothesis that circ-0034880-enriched tumor-derived extracellular vesicles (TEVs) mediate
-
Exosomal miRNAs: the tumor's trojan horse in selective metastasis Mol. Cancer (IF 27.7) Pub Date : 2024-08-20 Mobina Bayat, Javid Sadri Nahand
Organs of future metastasis are not passive receivers of circulating tumor cells, but are instead selectively and actively modified by the primary tumor before metastatic spread has even occurred. Tumors orchestrate a pre-metastatic program by conditioning distant organs to create microenvironments that foster the survival and proliferation of tumor cells before their arrival, thereby establishing
-
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research Mol. Cancer (IF 27.7) Pub Date : 2024-08-14 Aurélie Moniot, Christophe Schneider, Laure Chardin, Elisa Yaniz-Galende, Catherine Genestie, Marion Etiennot, Aubéri Henry, Coralie Drelon, Audrey Le Formal, Benoit Langlois, Laurence Venat, Christophe Louvet, Laure Favier, Alain Lortholary, Dominique Berton-Rigaud, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Coraline Dubot, Jean Emmanuel Kurtz, Nathalie Bonichon Lamichhane
Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC, many patients will relapse and the PARPi-resistant setting is an area of unmet medical need. Traditional immunotherapies targeting PD-1/PD-L1 have failed to show any benefit in OC. The CD47/TSP-1 axis
-
Novel humanized monoclonal antibodies against ROR1 for cancer therapy Mol. Cancer (IF 27.7) Pub Date : 2024-08-13 Rong Wei, Xun Liao, Jiao Li, Xiaoyu Mu, Yue Ming, Yong Peng
Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for cancer treatment. This study aimed to develop novel humanized ROR1 monoclonal antibodies and investigate their anti-tumor effects. ROR1 expression in tumor tissues
-
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions Mol. Cancer (IF 27.7) Pub Date : 2024-08-10 Hongyao Li, Xiang Wen, Yueting Ren, Zhichao Fan, Jin Zhang, Gu He, Leilei Fu
The Phosphatidylinositol-3-kinase (PI3K) family is well-known to comprise three classes of intracellular enzymes. Class I PI3Ks primarily function in signaling by responding to cell surface receptor stimulation, while class II and III are more involved in membrane transport. Under normal physiological conditions, the PI3K signaling network orchestrates cell growth, division, migration and survival
-
A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma Mol. Cancer (IF 27.7) Pub Date : 2024-08-09 Zhiyi Han, Tao Li, Heng Zhang, Kai Liang, Mingcong You, Mengdi Xu, Fan Bai, Tongmei Zhang
This study details a case of a patient with advanced lung adenocarcinoma harboring an exon 19 deletion in the EGFR gene. A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma, with multiple bone and lymph node metastases. Following the identification of tumor-specific antigen peptides, the patient received a combination treatment of immunotherapy (TSA-DC-CTL) and oral osimertinib
-
Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study Mol. Cancer (IF 27.7) Pub Date : 2024-08-09 Jin Li, Jihong Liu, Rutie Yin, Dongling Zou, Hong Zheng, Junning Cao, Zhendong Chen, Wei Sun, Yunong Gao, Songling Zhang, Linjuan Zeng, Ruifang An, Xianping Lu, Shuang Ye, Xiaohua Wu
Platinum-resistant or refractory ovarian cancer is a highly lethal gynecologic disease with limited treatment options. Chiauranib is a novel small-molecule selective inhibitor, which could effectively target multiple pathways including Aurora B and CSF-1R to inhibit cell cycle process and improve anti-tumor immune function, as long as VEGF pathway for tumor extinction. A phase II study was sequentially
-
Refining the diagnostic utility of OLFM4 in gastric cancer precursors: a call for rigorous methodologies Mol. Cancer (IF 27.7) Pub Date : 2024-08-08 Tai Zhang, Xudong Tang
This commentary offers a thoughtful discussion of the study by Wei et al. published in the journal on the role of Olfactomedin 4 (OLFM4) in incomplete intestinal metaplasia, a gastric precancerous condition. The original paper introduces OLFM4 as a novel biomarker with potential enhanced diagnostic efficacy compared to established markers. However, several methodological and interpretive considerations
-
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers Mol. Cancer (IF 27.7) Pub Date : 2024-08-07 Annamaria Salvati, Giorgio Giurato, Jessica Lamberti, Ilaria Terenzi, Laura Crescenzo, Viola Melone, Luigi Palo, Alessandro Giordano, Francesco Sabbatino, Giuseppina Roscigno, Cristina Quintavalle, Gerolama Condorelli, Francesca Rizzo, Roberta Tarallo, Giovanni Nassa, Alessandro Weisz
Identifying master epigenetic factors controlling proliferation and survival of cancer cells allows to discover new molecular targets exploitable to overcome resistance to current pharmacological regimens. In breast cancer (BC), resistance to endocrine therapy (ET) arises from aberrant Estrogen Receptor alpha (ERα) signaling caused by genetic and epigenetic events still mainly unknown. Targeting key
-
Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway Mol. Cancer (IF 27.7) Pub Date : 2024-08-06 Du Fei, Fang Wang, Yaohui Wang, Ji Chen, Shendong Chen, Lianpeng Fan, Luhan Yang, Qingyi Ren, Suwit Duangmano, Fukuan Du, Hao Liu, Jie Zhou, Jing Sheng, Yueshui Zhao, Xu Wu, Mingxing Li, Zhangang Xiao, Zhuo Zhang, Xian Jiang
Circular RNA (circRNA) is thought to mediate the occurrence and development of human cancer and usually acts as a tiny RNA (miRNA) sponge to regulate downstream gene expression. However, it is not clear whether and how circACVR2A (hsa_circ_0001073) is involved in the progression of HCC. The purpose of this study is to clarify the potential role and molecular mechanism of circACVR2A in regulating the
-
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance Mol. Cancer (IF 27.7) Pub Date : 2024-08-05 Ksenija Nesic, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya Kwan, Elizabeth Lieschke, Gwo-Yaw Ho, Holly E. Barker, Justin Bedo, Silvia Casadei, Andrew Farrell, Marc Radke, Kristy Shield-Artin, Jocelyn S. Penington, Franziska Geissler, Elizabeth Kyran, Robert Betsch, Lijun Xu, Fan Zhang, Alexander Dobrovic, Inger Olesen, Rebecca Kristeleit, Amit Oza, Iain McNeish
PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance is common. Multiple resistance mechanisms have been described, including secondary mutations that restore the HR gene reading frame. BRCA1 splice isoforms △11 and △11q can contribute
-
Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts Mol. Cancer (IF 27.7) Pub Date : 2024-08-02 De-Zhen Guo, Xin Zhang, Sen-Quan Zhang, Shi-Yu Zhang, Xiang-Yu Zhang, Jia-Yan Yan, San-Yuan Dong, Kai Zhu, Xin-Rong Yang, Jia Fan, Jian Zhou, Ao Huang
Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis. The heterogeneity of hepatocellular carcinoma (HCC) in cellular level is not clear. Integration analysis of single-cell RNA sequencing data and spatial transcriptomics data was performed. Multiple methods were applied to investigate the subtype of HCC tumor cells. The functional
-
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer Mol. Cancer (IF 27.7) Pub Date : 2024-08-02 Prashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, Joseph Cave, Joseph D. Butner, Carmine Schiavone, Dan G. Duda, Ahmed O. Kaseb, Caroline Chung, Eugene J. Koay, Vittorio Cristini, Bulent Ozpolat, George A. Calin, Zhihui Wang
Elevated microRNA-155 (miR-155) expression in non-small-cell lung cancer (NSCLC) promotes cisplatin resistance and negatively impacts treatment outcomes. However, miR-155 can also boost anti-tumor immunity by suppressing PD-L1 expression. Therapeutic targeting of miR-155 through its antagonist, anti-miR-155, has proven challenging due to its dual molecular effects. We developed a multiscale mechanistic
-
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy Mol. Cancer (IF 27.7) Pub Date : 2024-08-02 Yumi Oh, Sujeong Kim, Yunjae Kim, Hyun Kim, Dongjun Jang, Seungjae Shin, Soo-Jin Lee, Jiwon Kim, Sang Eun Lee, Jaeik Oh, Yoojin Yang, Dohee Kim, Hae Rim Jung, Sangjin Kim, Jihui Kim, Kyungchan Min, Beomki Cho, Hoseok Seo, Dohyun Han, Hansoo Park, Sung-Yup Cho
Immune checkpoint therapy (ICT) provides durable responses in select cancer patients, yet resistance remains a significant challenge, prompting the exploration of underlying molecular mechanisms. Tyrosylprotein sulfotransferase-2 (TPST2), known for its role in protein tyrosine O-sulfation, has been suggested to modulate the extracellular protein-protein interactions, but its specific role in cancer
-
Cancer, metastasis, and the epigenome Mol. Cancer (IF 27.7) Pub Date : 2024-08-02 Saurav Kiri, Tyrone Ryba
Cancer is the second leading cause of death worldwide and disease burden is expected to increase globally throughout the next several decades, with the majority of cancer-related deaths occurring in metastatic disease. Cancers exhibit known hallmarks that endow them with increased survival and proliferative capacities, frequently as a result of de-stabilizing mutations. However, the genomic features
-
Super-enhancer omics in stem cell Mol. Cancer (IF 27.7) Pub Date : 2024-08-01 Hongying Ma, Jian Qu, Zicheng Pang, Jian Luo, Min Yan, Weixin Xu, Haihui Zhuang, Linxin Liu, Qiang Qu
The hallmarks of stem cells, such as proliferation, self-renewal, development, differentiation, and regeneration, are critical to maintain stem cell identity which is sustained by genetic and epigenetic factors. Super-enhancers (SEs), which consist of clusters of active enhancers, play a central role in maintaining stemness hallmarks by specifically transcriptional model. The SE-navigated transcriptional
-
Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer Mol. Cancer (IF 27.7) Pub Date : 2024-07-31 Hong-Xiang Shi, Hang-Tian Tao, Jin-Jin He, Feng-Yi Zhu, Cui-Qing Xie, Yu-Na Cheng, Li-Li Hou, Hua Sun, Chang-Jiang Qin, Dong Fang, Song-Qiang Xie
Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibitor targeting PD-1/PD-L1 was only used to treat a small proportion of metastatic triple-negative breast cancer (TNBC), and the clinical outcomes was very limited. In addition, this regimen cannot
-
Circular RNA hsa_circ_0000467 promotes colorectal cancer progression by promoting eIF4A3-mediated c-Myc translation Mol. Cancer (IF 27.7) Pub Date : 2024-07-31 Xianjie Jiang, Mingjing Peng, Qiang Liu, Qiu Peng, Linda Oyang, Shizhen Li, Xuemeng Xu, Mengzhou Shen, Jiewen Wang, Haofan Li, Nayiyuan Wu, Shiming Tan, Jinguan Lin, Longzheng Xia, Yanyan Tang, Xia Luo, Qianjin Liao, Yujuan Zhou
Colorectal cancer (CRC) is the second most common malignant tumor worldwide, and its incidence rate increases annually. Early diagnosis and treatment are crucial for improving the prognosis of patients with colorectal cancer. Circular RNAs are noncoding RNAs with a closed-loop structure that play a significant role in tumor development. However, the role of circular RNAs in CRC is poorly understood
-
Decoding the spatiotemporal heterogeneity of tumor-associated macrophages Mol. Cancer (IF 27.7) Pub Date : 2024-07-27 Xiangyuan Chu, Yu Tian, Chao Lv
Tumor-associated macrophages (TAMs) are pivotal in cancer progression, influencing tumor growth, angiogenesis, and immune evasion. This review explores the spatial and temporal heterogeneity of TAMs within the tumor microenvironment (TME), highlighting their diverse subtypes, origins, and functions. Advanced technologies such as single-cell sequencing and spatial multi-omics have elucidated the intricate
-
Correction: Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression Mol. Cancer (IF 27.7) Pub Date : 2024-07-25 Rajakishore Mishra, Siddavaram Nagini, Ajay Rana
Correction: Mol Cancer 14, 20 (2015) https://doi.org/10.1186/s12943-015-0300-x Following publication of the original article [1], the authors learned that an incorrect representative IHC image (Fig. 1n) for GSK3beta was used. We have identified the error and would like to replace it with the corrected Fig. 1n. The image replacement does not alter the paper's conclusions, and our proposed hypothesis
-
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches Mol. Cancer (IF 27.7) Pub Date : 2024-07-25 Fangfang Liu, Jingyu Chen, Kai Li, Haochen Li, Yiyi Zhu, Yubo Zhai, Bingbing Lu, Yanle Fan, Ziyue Liu, Xiaojie Chen, Xuechao Jia, Zigang Dong, Kangdong Liu
Ubiquitination, a pivotal posttranslational modification of proteins, plays a fundamental role in regulating protein stability. The dysregulation of ubiquitinating and deubiquitinating enzymes is a common feature in various cancers, underscoring the imperative to investigate ubiquitin ligases and deubiquitinases (DUBs) for insights into oncogenic processes and the development of therapeutic interventions
-
Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy Mol. Cancer (IF 27.7) Pub Date : 2024-07-25 Andriani Angelopoulou, Giorgos Theocharous, Dimitrios Valakos, Aikaterini Polyzou, Sophia Magkouta, Vassilios Myrianthopoulos, Sophia Havaki, Marco Fiorillo, Ioanna Tremi, Konstantinos Vachlas, Theodoros Nisotakis, Dimitris-Foivos Thanos, Anastasia Pantazaki, Dimitris Kletsas, Jiri Bartek, Russell Petty, Dimitris Thanos, Rory J McCrimmon, Angelos Papaspyropoulos, Vassilis G Gorgoulis
Non-small cell lung cancer (NSCLC) constitutes one of the deadliest and most common malignancies. The LKB1/STK11 tumour suppressor is mutated in ∼ 30% of NSCLCs, typically lung adenocarcinomas (LUAD). We implemented zebrafish and human lung organoids as synergistic platforms to pre-clinically screen for metabolic compounds selectively targeting LKB1-deficient tumours. Interestingly, two kinase inhibitors
-
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives Mol. Cancer (IF 27.7) Pub Date : 2024-07-16 Zhaoyang Zhu, Yigang Jin, Jing Zhou, Fei Chen, Minjie Chen, Zhaofeng Gao, Lingyu Hu, Jinyan Xuan, Xiaoping Li, Zhengwei Song, Xiao Guo
The advent of PD1/PD-L1 inhibitors has significantly transformed the therapeutic landscape for clear cell renal cell carcinoma (ccRCC). This review provides an in-depth analysis of the biological functions and regulatory mechanisms of PD1 and PD-L1 in ccRCC, emphasizing their role in tumor immune evasion. We comprehensively evaluate the clinical efficacy and safety profiles of PD1/PD-L1 inhibitors